Perrigo Company PLC (PRGO)
|Net Income (ttm)||-349.20M|
|Ex-Dividend Date||Sep 2, 2021|
|Day's Range||45.28 - 46.08|
|52-Week Range||37.56 - 50.90|
|Price Target||57.00 (+24.9%)|
|Est. Earnings Date||Nov 10, 2021|
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digest... [Read more...]
Financial PerformanceFinancial Statements
According to 5 analysts, the average rating for Perrigo stock is "Hold." The 12-month stock price forecast is 57.00, which is an increase of 24.95% from the latest price.
A couple of months back we discussed that Perrigo stock can see higher levels after it fell 15% following a Q2 miss. PRGO stock has since risen over 17% to levels of $48 currently.
DUBLIN, Oct. 5, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products, today announced that Jim Dillard, currently E...
The drug company is collecting money at the same time it was able to pare back a big tax bill.
Perrigo (PRGO) agrees to pay an aggregate of approximately $345 million (Euro 297 million) to settle its tax liability notice from the Irish Office of the Revenue Commissioners issued in 2018.
Find out what happened overnight that could move the stock market.
Over-the-counter drugs company Perrigo Company plc (NYSE:PRGO) has settled the tax bill issued for €297 million. When credit for certain taxes already paid is factored in, the cash payment that Perrigo...
DUBLIN, Sept. 29, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) ("Perrigo" or the "Company"), a leading provider of Quality, Affordable Self-Care Products, today announced that it has reac...
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care comp...
In a statement, Perrigo Company PLC (NYSE: PRGO) announced that it had inked a deal, and the company is set to acquire Héra SAS. The acquisition will make Perrigo the world leader in the consumer self-c...
Perrigo Company plc (NYSE: PRGO) will acquire HRA Pharma, a consumer self-care company, from Astorg and Goldman Sachs Asset Management. The transaction is valued at €1.8 billion, or approximately $2.1 b...
It's only a good deal if the stock in question is likely to recover sooner rather than later.
Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 to ensure each index is more representative o...
DUBLIN, Sept. 3, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that Perrigo President and CEO, Murray S.
We believe that Perrigo stock, a healthcare company that provides over-the-counter self-care products, looks like a good buying opportunity at the present time. PRGO stock trades near $41 currently and ...
Deep value dividend stocks aren't just cheap; they have high yields and higher growth potential, making a potent mix for any investor's portfolio. The post 3 Undervalued Dividend Stocks to Buy For High ...
Analysts cooled on the company's prospects following its latest earnings report.
The price of Perrigo stock, a healthcare company that provides over-the-counter self-care products, has seen a 10% fall over the last five trading days, and much of this fall has come in yesterday's tra...
A disappointing earnings report pushed down shares of the over-the-counter medicine seller.
Perrigo Company plc (NYSE: PRGO) has posted Q2 sales of $981 million, an increase of 3.4% Y/Y, missing the consensus of $1.02 billion. The sales growth was primarily due to an increase in most businesse...
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
Perrigo Co plc (NYSE: PRGO) said on Wednesday it concluded its fiscal second quarter in loss. The NYSE-listed shares of the company were down more than 10% this morning on weak guidance for the future.
Perrigo (PRGO) delivered earnings and revenue surprises of -18.03% and -3.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, Aug. 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, today announced financial results from continuing operations for t...